This study aimed to evaluate the efficacy and safety of the combination of modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) as the frist line chemotherapy in patients with advanced and recurrent gastric cancer who no longer curable Methods: This is a mixed study of retrospective and prospective cohorts, involving 32 patients diagnosed with advanced gastric cancer in K Hospital who underwent mDCF as first-line chemotherapy.